Supreme Court Keeps Telehealth Abortion Access Intact for Now

The Supreme Court on Thursday blocked a sweeping Fifth Circuit order that would have banned telehealth prescriptions of mifepristone nationwide, preserving access to medication abortion for patients in states with bans and beyond. The emergency ruling came after lower courts moved to restrict the drug’s distribution through the mail, but the decision leaves the conservative dissenters openly plotting the next phase of restrictions.

Justices Clarence Thomas and Samuel Alito issued sharp dissents that framed the majority’s action as an end-run around the 2022 Dobbs decision. Alito described the outcome as part of a “scheme” to undermine state-level abortion bans, while Thomas invoked the long-dormant Comstock Act of 1873 to argue that mailing abortion medication is already illegal under federal law. Both justices pointed to data showing that abortions have risen since Dobbs, largely because patients in restrictive states can now obtain mifepristone through telehealth without traveling.

Recent figures underscore the shift. In 2025, more residents of states with total bans received medication abortions via telehealth than crossed state lines for in-clinic care. Roughly two-thirds of all U.S. abortions in 2023 were medication procedures, a trend that has accelerated as providers adapted to post-Dobbs realities. Advocates say this expansion has kept care available even as legislatures moved aggressively to close clinics.

The immediate threat to mifepristone distribution has eased for now, according to Claire Teylouni of Reproductive Equity Now, who described the ruling as a temporary reprieve. Yet the dissents make clear that conservative justices view the Comstock Act as a ready tool for future litigation. Thomas wrote that providers are not entitled to relief based on “lost profits from their criminal enterprise,” signaling willingness to treat routine medical distribution as a federal offense.

The fight over medication abortion overlaps with broader efforts to limit reproductive autonomy, including voting-rights restrictions that reduce political power in states where abortion remains legal. Progressive groups have struggled to frame these connected battles for the public, even as polling shows majority support for access. A separate win for free-speech protections in a related Federal Trade Commission case involving Media Matters offered a narrow counterpoint, but it has not altered the trajectory on abortion.

Legal observers note that the Court’s emergency order does not resolve underlying questions about the Food and Drug Administration’s approval of mifepristone or the reach of the Comstock Act. Providers and patients in ban states continue to rely on telehealth, but the dissenting opinions have already supplied a roadmap for the next round of challenges. With medication abortion now the dominant method of care, any successful revival of nineteenth-century mailing bans would affect far more people than the clinic closures that followed Dobbs.

The ruling buys time for patients and clinics adapting to patchwork state laws, yet it also confirms that the justices who overturned Roe remain focused on further limits. As states experiment with enforcement mechanisms and federal statutes are dusted off for new purposes, the terrain for reproductive care remains unsettled.